The Hidden Risks of Outsourcing PV (and How to Mitigate Them)
Outsourcing pharmacovigilance (PV) activities can be a practical and cost-effective solution, particularly for smaller sponsors or organisations without an established internal PV function.
A specialist provider can bring expertise, established processes, systems, and additional capacity without requiring a sponsor to build an entire pharmacovigilance department.
But outsourcing does not outsource responsibility.
For sponsors, one of the biggest risks is assuming that once a PV activity has been handed to a third party, the associated compliance risk has been handed over as well.
It has not.
The sponsor remains responsible for ensuring that its pharmacovigilance system operates effectively and that regulatory obligations are met. The challenge is therefore not simply choosing a capable PV vendor, but establishing appropriate oversight of the relationship.
1. Assuming the Vendor Owns the Regulatory Responsibility
This is one of the most fundamental outsourcing misconceptions.
A contract may transfer operational activities to a service provider, but it does not transfer the sponsor's regulatory responsibility.
If a case is not reported on time, a safety signal is missed, or an important safety issue is not escalated appropriately, the sponsor may still be held accountable.
How to mitigate it:
Clearly define responsibilities between the sponsor and vendor, including:
Case intake and processing
Medical assessment
Regulatory reporting
Follow-up
Signal management
Safety monitoring
Escalation
Record keeping
Regulatory communications
There should be no ambiguity about who does what, when, and how the sponsor maintains oversight.
2. Choosing a Vendor Based on Price Alone
Cost is understandably an important consideration, particularly for smaller companies.
However, the cheapest PV provider may not necessarily be the most appropriate provider for the sponsor's risk profile.
A vendor may offer an attractive price but lack:
Appropriate therapeutic expertise
Experience with the sponsor's product type
Local regulatory knowledge
Adequate staffing
Appropriate quality systems
Capacity to manage fluctuations in workload
How to mitigate it:
Vendor selection should consider competence, capacity, experience, quality, regulatory knowledge, business continuity, and scalability, in addition to cost.
The question should not simply be "How much does the service cost?"
It should be "Can this vendor reliably perform the activities we are entrusting to them?"
3. Assuming a Signed Quality or PV Agreement Is Enough
Having a pharmacovigilance agreement in place is important, but the existence of an agreement does not demonstrate effective vendor oversight.
A well-written agreement can still fail in practice if:
Responsibilities are not understood
Timelines are not followed
Contact details become outdated
Escalation pathways are unclear
The sponsor never reviews vendor performance
How to mitigate it:
Treat the agreement as the foundation of the relationship, not the end of the oversight process.
Responsibilities should be reviewed periodically, particularly when there are changes to products, markets, vendors, systems, or regulatory requirements.
4. Failing to Understand the Vendor's Procedures
Sponsors often assume that a vendor's SOPs will automatically align with their own.
They may not.
The vendor may use different terminology, workflows, escalation criteria, databases, or timelines.
This becomes particularly important where a vendor operates across multiple jurisdictions.
For an Australian sponsor, a global vendor may have highly developed processes based primarily on EU or US requirements. Those processes may not fully address Australian-specific requirements.
How to mitigate it:
Sponsors should understand how the vendor's processes interact with their own PV system and ensure that Australian requirements are specifically addressed where applicable.
The objective is not to force the vendor to adopt the sponsor's SOPs. It is to ensure that the combined system works and meets the applicable regulatory requirements.
5. Losing Visibility of What Happens to Individual Cases
Once case processing is outsourced, sponsors can become disconnected from the details.
Reports may be received as periodic summaries rather than through direct involvement in the underlying process.
This can make it difficult for the sponsor to understand:
Why cases were classified in a particular way
Whether follow-up was attempted
Why a report was or was not submitted
Whether timelines were met
Whether recurring issues are emerging
How to mitigate it:
Establish appropriate reporting and oversight metrics.
Depending on the arrangement, these may include:
Number of cases received
Case processing timelines
Reporting compliance
Follow-up performance
Reconciliation results
Deviations
Quality issues
CAPAs
The sponsor does not need to duplicate the vendor's work, but it does need enough visibility to exercise meaningful oversight.
6. Poor Communication Between Sponsor and Vendor
Even technically strong PV arrangements can fail because of communication.
For example, a vendor may identify a safety concern but not know that the sponsor's quality team is investigating a related complaint.
Alternatively, the sponsor may make a product or labelling change without informing the vendor.
How to mitigate it:
Establish clear communication channels and escalation contacts.
Regular meetings can be particularly useful for reviewing:
Safety issues
Reporting performance
Emerging trends
Deviations
Changes to products
Changes to processes
Upcoming regulatory activities
Communication should be proportionate to the complexity and risk of the relationship.
7. Insufficient Vendor Training
Sponsors often focus heavily on training their own employees while assuming that a specialist PV vendor does not require additional training.
However, the vendor may not be familiar with the sponsor's specific products, processes, safety information sources, or Australian requirements.
This can be particularly relevant where third parties interact directly with consumers.
How to mitigate it:
Provide appropriate sponsor-specific training to relevant vendor personnel and maintain evidence of that training.
Training should cover the information they need to perform their role effectively, including relevant product information, escalation requirements, reporting pathways, and any sponsor-specific procedures.
8. Not Monitoring Vendor Performance
A vendor can perform well initially and gradually develop performance issues as circumstances change.
Staff turnover, increased case volumes, new products, system changes, or organisational restructuring can all affect performance.
A sponsor that only assesses a vendor during initial qualification may not identify these problems until they become significant.
How to mitigate it:
Implement ongoing vendor monitoring.
This may include:
Performance indicators
Periodic service reviews
Quality reviews
Reconciliation
Deviation tracking
CAPA monitoring
Periodic audits where appropriate
The level of oversight should be proportionate to the criticality of the outsourced activity.
9. Vendor Staff Turnover
Outsourcing can create the impression that expertise is embedded within the vendor organisation.
In reality, the people performing the work may change.
When experienced vendor staff leave, knowledge about a sponsor's products, processes, and historical safety issues can be lost.
How to mitigate it:
Sponsors should ensure that vendors have appropriate training, documentation, knowledge transfer, and continuity arrangements.
Where activities are particularly critical, the sponsor should understand how the vendor manages key-person dependency.
10. Business Continuity Is Often Overlooked
What happens if your PV vendor's system goes down?
What happens if the vendor experiences a cyber incident, staffing shortage, natural disaster, or other major disruption?
Outsourcing can create concentration risk because a significant part of the sponsor's PV system may depend on one external organisation.
How to mitigate it:
Business continuity should be considered during vendor qualification and throughout the relationship.
Sponsors should understand:
The vendor's business continuity arrangements
Disaster recovery capabilities
Backup arrangements
Alternative communication channels
Critical system dependencies
Escalation procedures
For critical PV activities, sponsors should know what happens if the vendor cannot perform.
11. Assuming "Global" Means "Compliant Everywhere"
Global PV vendors can be highly capable, but global processes do not automatically equal local compliance.
Australian requirements may differ from those applicable in the vendor's primary markets.
A vendor's global SOP may therefore need local procedures, work instructions, or contractual requirements to ensure that Australian obligations are addressed.
How to mitigate it:
Identify which activities require Australian-specific consideration and ensure that local requirements are incorporated into the operating model.
This is particularly important for:
Australian adverse event reporting
Local regulatory communications
Australian product portfolios
Local PV contacts
TGA enquiries and inspections
12. Failing to Reconcile Data
When different systems are used by the sponsor and vendor, discrepancies can develop.
For example, the number of cases recorded by the sponsor may not match the number recorded by the vendor.
Without reconciliation, cases can potentially be overlooked or duplicated.
How to mitigate it:
Define reconciliation responsibilities, frequency, methodology, and escalation procedures.
Reconciliation should be treated as a meaningful quality activity rather than a box-ticking exercise.
13. Not Auditing the Vendor When Appropriate
Some sponsors are reluctant to audit vendors because the vendor is an established provider or because auditing is considered too costly.
However, the criticality of the outsourced activity should determine the level of oversight.
For a vendor performing key pharmacovigilance activities, the sponsor should have an appropriate mechanism for assessing whether the vendor continues to meet agreed requirements.
How to mitigate it:
Use a risk-based approach to vendor audits and assessments.
An audit is not necessarily required every year. The appropriate frequency and method should reflect the risk, complexity, performance history, and nature of the services provided.
14. Forgetting That the Sponsor's PV System Includes Its Vendors
Perhaps the biggest conceptual mistake is thinking of the vendor as separate from the pharmacovigilance system.
From a regulatory perspective, outsourced activities form part of the sponsor's overall PV system.
If the vendor receives adverse event information, processes cases, conducts literature monitoring, or performs other safety activities on behalf of the sponsor, those activities need to be integrated into the sponsor's governance framework.
How to mitigate it:
Map the complete PV process from the initial receipt of safety information through to assessment, reporting, follow-up, and closure.
Identify where each activity occurs, who performs it, and how the sponsor maintains oversight.
Conclusion
Outsourcing pharmacovigilance can provide significant benefits. It can give sponsors access to specialist expertise, established infrastructure, and flexible resources without requiring a large internal PV function.
The risk arises when outsourcing is treated as a transfer of responsibility rather than a transfer of activities.
A strong sponsor-vendor relationship should provide clear accountability, appropriate communication, ongoing oversight, and evidence that the outsourced activities are actually working as intended.
The most important question is therefore not simply whether your PV vendor is competent.
It is whether you, as the sponsor, can demonstrate that you know what your vendor is doing, that you have appropriate oversight of those activities, and that the overall pharmacovigilance system remains effective.
Outsourcing can be part of a robust PV strategy. It should never become a blind spot within it.
